Evommune: A Biotech Worth a Punt?

by

Now, most folks look at biotech firms and see a lottery ticket dressed up in a lab coat. And they wouldn’t be entirely wrong. It’s a world of hopefuls and almost-therapies, where fortunes are made and lost on the whim of a clinical trial. But every so often, a little spark of something…promising…appears. Evommune, a name that sounds suspiciously like a minor deity in a forgotten pantheon1, is currently attempting to fan that spark into a flame. The question is, is it worth risking a few shillings on the venture?

Small-cap biotechs are, let’s be honest, spectacularly risky. For every one that blossoms into a pharmaceutical giant, a dozen wither and fade, leaving behind only disappointed investors and a mountain of unfulfilled promises. It’s the natural order of things, really. The universe has a peculiar fondness for proving people wrong. But Evommune…well, it’s got a few things going for it. And in this business, a few things can be the difference between a ten-bagger and a spectacular bonfire of cash.

What Makes Evommune Tick?

This upstart, fresh from the alchemical crucible of an IPO last November, is focused on autoimmune conditions. A perfectly sensible thing to target, given that the human body seems to have a distinct talent for attacking itself. Their primary candidate, EVO756, is aiming for blockbuster status, which is a term that always sounds a bit like a particularly aggressive breed of garden gnome. It’s currently in phase 2b trials for chronic spontaneous urticaria – hives that appear for no discernible reason. Which, if you think about it, is the most terrifying kind of hive.

Loading widget...

Now, most urticaria treatments just try to suppress the symptoms, like putting a rug over a particularly nasty hole in the floor. EVO756, however, is going after the root cause – a little thing called MRGPRX2. Think of it as a volume knob on mast cells – those pesky little things that release histamine and cause all the itching and swelling. Turn the knob down, and the chaos subsides. A beautifully elegant solution, if it works. And they’re also looking at atopic dermatitis – eczema – with the same drug. Early data suggests a clinical response in a remarkable 93% of patients after just four weeks. Which, frankly, sounds too good to be true.2

Analysts at William Blair – those keen observers of the financial landscape – reckon EVO756 could peak at $5 billion in sales by 2035. That’s a lot of ointment. Success in urticaria alone would be enough to send the share price soaring, and success in atopic dermatitis would open up a whole new world of possibilities. And with Incyte recently splashing out $750 million for Escient Pharmaceuticals – a company also playing in the MRGPRX2 space – Evommune is starting to look like a rather attractive acquisition target. A larger pharmaceutical company might just decide it needs a piece of the action.

They’re also working on EVO301, a fusion protein targeting the IL-18 inflammatory pathway. It’s showing promise in atopic dermatitis trials, with a 55% reduction in eczema severity compared to 22% for a placebo. That’s a significant improvement, and a welcome sign that Evommune isn’t just a one-trick pony. They’re even planning a phase 2 trial for ulcerative colitis. The ambition, it has to be said, is commendable.

The Numbers, Such as They Are

As of the end of 2025, Evommune had a respectable $216.7 million in cash. Which, in the world of biotech, is roughly equivalent to a small kingdom. They reckon that, along with proceeds from a recent fundraising round, it’ll keep them afloat until 2028. Which gives them a bit of breathing room. They’re still losing money, of course. A net loss of $68.9 million in 2025 is nothing to sneeze at. But they’ve increased revenue to $13 million, thanks to a licensing deal with a Japanese pharmaceutical company. Every little bit helps.

A Calculated Gamble?

Could Evommune deliver a ten-fold return on investment over the next decade? It’s certainly possible. They only have two therapies in the clinic right now, but if either one gets approved, it could provide the financial muscle to push the other one over the finish line. This isn’t an investment for the faint of heart, mind you. With a market cap of only $835 million, the shares are likely to be volatile. But they already appear to have the science to make them an attractive target for a takeover or a partnership deal. And either outcome could send the share price into orbit.

So, is Evommune worth a punt? Well, as any seasoned gambler will tell you, there are no guarantees. But in a world of risk and uncertainty, a little bit of calculated speculation can sometimes pay off handsomely. Just don’t bet the farm.

  1. The name is derived from the Old High Germanic “Evo,” meaning “everlasting,” and “Mune,” a forgotten deity of cellular regulation. Or so the legend goes.
  2. Which, of course, raises the question: what were the patients responding to? The placebo effect is a powerful thing, but 93%? One suspects a generous dose of statistical wizardry.

Read More

2026-03-10 16:52